Indications
Krystexxa is indicated for the treatment of severe debilitating chronic tophaceous gout in adult patients who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these medicines are contraindicated.
Composition
- Active substance
- pegloticase
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Krystexxa
- Active substance
- pegloticase
- ATC code
- M04AX02
- Therapeutic area
- Gout
- Marketing authorisation holder
- Crealta Pharmaceuticals Ireland Limited